Trinity Biotech (TRIB) Gross Margin (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly Gross Margin of 30.76% for Q4 2024, down 325.0% year-on-year from 13.67% in Q1 2024, and down 12.2% on a QoQ basis from 35.03% in Q3 2024.
Trinity Biotech (TRIB) Gross Margin (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported Gross Margin for 16 consecutive years, with 30.76% the latest figure, recorded in Q4 2024.
- Quarterly Gross Margin fell 325.0% year-over-year to 30.76% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 34.83% (up 61.0% YoY) and the FY2025 annual result came in at 38.57%, up 374.0% from the prior year.
- Gross Margin declined to 30.76% in Q4 2024 per TRIB's latest filing, from 35.03% in the prior quarter.
- Over the last five years, Gross Margin for TRIB reached as high as 52.4% in Q3 2020 and fell as low as 2.1% in Q3 2022.
- A 5-year average of 36.84% and a median of 37.31% in 2021 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin slumped 3835 bps — and 2023, when it surged 2707 bps.
- Year by year, Gross Margin stood at 47.79% in 2020, then decreased by 22 bps to 37.08% in 2021, then fell by 8 bps to 34.18% in 2022, then fell by 0 bps to 34.01% in 2023, then dropped by 10 bps to 30.76% in 2024.
- According to Business Quant data, Gross Margin over the past three periods registered 30.76%, 35.03%, and 36.19% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 30.76% |
| Sep 30, 2024 | 35.03% |
| Jun 30, 2024 | 36.19% |
| Mar 31, 2024 | 37.55% |
| Dec 31, 2023 | 34.01% |
| Sep 30, 2023 | 29.16% |
| Jun 30, 2023 | 36.19% |
| Mar 31, 2023 | 37.58% |
| Dec 31, 2022 | 34.18% |
| Sep 30, 2022 | 2.10% |
| Jun 30, 2022 | 36.20% |
| Mar 31, 2022 | 38.16% |
| Dec 31, 2021 | 37.08% |
| Sep 30, 2021 | 40.45% |
| Jun 30, 2021 | 42.67% |
| Mar 31, 2021 | 42.64% |
| Dec 31, 2020 | 47.79% |
| Sep 30, 2020 | 52.40% |
| Jun 30, 2020 | 42.88% |
| Mar 31, 2020 | 43.80% |